Market Overview

Benzinga's Top Initiations

Related SPPI
Mid-Afternoon Market Update: Markets Mixed as iRobot Surges
Mid-Day Market Update: U.S. Markets Extend Losses; Hewlett-Packard Shares Rise On Analyst Upgrade
Related GALT
Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Exoects GR-MD-02 Phase 1 Cohort 2 Result at End of July
Galectin Therapeutics (GALT) Falls: Stock Goes Down 11.3% - Tale of the Tape

Analysts at HC Wainwright initiated coverage on shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) with a “buy” rating. The target price for Spectrum Pharmaceuticals is set to $15. Spectrum's shares closed at $8.49 on Friday.

Ascendiant Capital initiated coverage on shares of Galectin Therapeutics (NASDAQ: GALT) with a “buy” rating. The target price for Galectin Therapeutics is set to $13. Galectin Therapeutics' shares closed at $11.00 on Friday.

Analysts at Morgan Stanley initiated coverage on shares ITC Holdings (NYSE: ITC) with an “overweight” rating. The target price for ITC Holdings is set to $105. ITC's stock closed at $93.13 on Friday.

Atlantic Equities initiated coverage on shares of Facebook (NASDAQ: FB) with an “overweight” rating. The target price for Facebook is set to $63. Facebook's shares closed at $51.04 on Friday.

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Most Popular

Related Articles (FB + GALT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free